Navigation Links
150-year-old Drug May Provide 'Off' Time Relief for People with Advanced Parkinson's Disease
Date:4/19/2017

BOSTON, April 19, 2017 /PRNewswire-USNewswire/ -- New research provides evidence that an old drug may provide relief for people with advanced Parkinson's, according to a study released today that will be presented at the American Academy of Neurology's 69th Annual Meeting in Boston, April 22 to 28, 2017.

When it comes to the treatment of Parkinson's disease, the oral drug levodopa has long been considered the gold standard, improving quality of life and longevity. But as the disease progresses, the effects of the medication can partially wear off more quickly after each dose, leaving people to experience "off" time, which are periods of immobility related to temporary unresponsiveness to medication. Parkinson's symptoms, such as slowness and muscle rigidity, often make movement difficult.

"If a person with Parkinson's disease can reduce their 'off' times, that can have a great impact on their everyday life," said study author Regina Katzenschlager, MD, of Danube Hospital, affiliated with the Medical University of Vienna, Austria. "In some patients in the trial, the insecurity of unpredictable periods of incapacity was completely alleviated."

The drug apomorphine, first produced in 1865, was first used to treat advanced Parkinson's disease in the United States in 1950. Its use grew in the 1990s when European doctors starting using subcutaneous infusions of the drug to treat fluctuations in mobility that could not be controlled by the pills. Despite its use in many countries of the world, high-level evidence from randomized, blinded studies of its effectiveness and safety has up until now been lacking.

In this phase III study, researchers recruited 107 people with advanced Parkinson's disease from 23 centers in seven countries. Participants were randomly selected to receive either apomorphine subcutaneous infusion or a placebo saline infusion. The infusion was administered over a period of 14 to 18 hours each day via a small portable pump similar to the sort used in the treatment of type 1 diabetes.

The study found that those who were given apomorphine had a significantly greater reduction of "off" time than those who were given the placebo infusion, with, on average, 2.5 hours less "off" time per day, while those who received the placebo infusion had an average 30 minutes per day reduction in "off" time. This improvement was apparent within the first week of treatment. At the same time, for those who received apomorphine, there was an increase of "on" time without the abnormal involuntary movements known as dyskinesias that are often observed with levodopa.

Participants were also asked to evaluate how well they thought the treatment worked. Those who received apomorphine gave their treatment higher scores at week 12 than those who received the placebo infusion. In the apomorphine group, 71 percent of patients felt improved, compared to 18 percent on placebo, whereas 19 percent worsened on apomorphine compared to 45 percent on placebo. Apomorphine was generally well tolerated and there were no serious side effects.

"It is our hope that these findings confirming the efficacy of apomorphine infusion will encourage doctors in the United States to offer this treatment to their patients and assess its efficacy in their own clinical practice," said Katzenschlager.

The study was supported by Britannia Pharmaceuticals Ltd., the maker of apomorphine.

Learn more about Parkinson's disease at www.aan.com/patients.

The American Academy of Neurology is the world's largest association of neurologists and neuroscience professionals, with 32,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, concussion, Parkinson's disease and epilepsy.

For more information about the American Academy of Neurology, visit http://www.aan.com or find us on Facebook, Twitter, Google+, LinkedIn and YouTube.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/150-year-old-drug-may-provide-off-time-relief-for-people-with-advanced-parkinsons-disease-300442207.html


'/>"/>
SOURCE American Academy of Neurology
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Information Online Market Research Portal Provides Complimentary Sample Service for Customers to Preview Reports by Global Industry Analysts
2. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
3. Novelos Therapeutics Provides Product Pipeline Update
4. Sony Biotechnology Inc.s New Technology for Science Provides Researchers Results in Color
5. Survey of Participants from Landmark GRACE Trial Provides Patients Perspectives from an HIV Clinical Study
6. Oncologix (OCLG) Plans Expansion; Talks Underway with Two Healthcare Service Providers
7. Ampio Pharmaceuticals Provides Clinical Updates
8. More Than 100 Winning Medicare Bidders In Maryland Dont Have Proper Licenses To Provide Medical Equipment To Patients
9. Life Care Medical Devices Provides Mid-Year 2013 Corporate Review and Outlines Near-Term Corporate Milestones
10. Neiman Center Issues Policy Brief Outlining Innovative Health Care Payment Models to Provide Cost-Effective Specialty Care for Patients
11. PDL BioPharma Provides Second Quarter 2013 Royalty Revenue Guidance of $143 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2019)... ... 2019 , ... Xpediant Digital, the leader in DAM Integration ... VP of Product Development. Surace has spent his career developing products, building complex ... Technology & Distribution at HMN, where he led software development, data analytics, and ...
(Date:3/20/2019)... FALLS CHURCH, Va. (PRWEB) , ... March 20, ... ... solutions and services for Federal and state public health agencies, today announced the ... With more than 15 years of professional consulting and contracts management experience supporting ...
(Date:3/20/2019)... AUSTIN, Texas (PRWEB) , ... ... ... HealthCarePoint (HCP), today announced release of ground-breaking mechanisms specifically designed ... care, stay in compliance with local and international regulations and continue to ...
Breaking Medicine Technology:
(Date:3/20/2019)... (PRWEB) , ... March 20, 2019 , ... ... Medical systems are being developed with Wi-Fi connectivity to allow portable devices to ... heart and hypertension monitoring, glucose monitoring, and other wearable devices for home healthcare ...
(Date:3/20/2019)... ... March 20, 2019 , ... TSI Healthcare, ... (PM) and Electronic Health Record (EHR) solutions, received multiple top awards in the ... the fifth consecutive year TSI Healthcare has been honored by this selective international ...
(Date:3/20/2019)... ... March 20, 2019 , ... ... pain from disc herniation's, degenerative disc disease, spinal stenosis, sciatica and numbness in ... location! , At Advanced Spine Joint and Wellness provider's work as a ...
(Date:3/20/2019)... CREEK, Calif. (PRWEB) , ... March 20, 2019 ... ... for the healthcare industry, announced today the launch of its mSource® Predictive Plan, ... customers the most complete insights. It gives purchased services teams the control to ...
(Date:3/20/2019)... ... March 20, 2019 , ... AutismOne has announced that Dr. Andrew Wakefield, an ... measles. Dr. Wakefield's presentation at the AutismOne 2019 Conference will address what herd immunity ... eras. The lecture will examine the consequences - real and potential - for vaccines ...
Breaking Medicine News(10 mins):